@article{BohlkenWeberSiebertetal.2017,
  author    = {Bohlken, Jens and Weber, Simon A. and Siebert, Anke and Forstmeier, Simon and Kohlmann, Thomas and Rapp, Michael A.},
  title     = {Reminiscence therapy for depression in dementia},
  series = {GeroPsych - The Journal of gerontopsychology and geriatric psychiatry},
  volume    = {30},
  journal   = {GeroPsych - The Journal of gerontopsychology and geriatric psychiatry},
  publisher = {Hogrefe},
  address   = {G{\"o}ttingen},
  issn      = {1662-9647},
  doi       = {10.1024/1662-9647/a000175},
  pages     = {145 -- 151},
  year      = {2017},
  abstract  = {We investigated the efficacy of reminiscence therapy (RT) on symptoms of depression in patients with mild to moderate dementia. Out of 227 patients with mild to moderate dementia from a specialized physician's office, 27 pairs (N = 54; mean age 79.04 ± 6.16 years) who had either received treatment as usual (TAU) or TAU combined with RT, were matched retrospectively according to age as well as cognitive and depressive symptom scores. After controlling for age and sex, symptoms of depression significantly decreased over time in the RT group compared to TAU (F1,52 = 4.36; p < .05). RT is a promising option for the treatment of depression in mild to moderate dementia. Larger randomized-controlled trials are needed.},
  language  = {en}
}
@inproceedings{GrumRappGronauetal.2019,
  author    = {Grum, Marcus and Rapp, Simon and Gronau, Norbert and Albers, Albert},
  title     = {Accelerating knowledge},
  series = {Business modeling and software design},
  volume    = {356},
  booktitle = {Business modeling and software design},
  editor    = {Shishkov, Boris},
  publisher = {Springer},
  address   = {Cham},
  isbn      = {978-3-030-24853-6},
  doi       = {10.1007/978-3-030-24854-3_7},
  pages     = {95 -- 113},
  year      = {2019},
  abstract  = {As knowledge-intensive processes are often carried out in teams and demand for knowledge transfers among various knowledge carriers, any optimization in regard to the acceleration of knowledge transfers obtains a great economic potential. Exemplified with product development projects, knowledge transfers focus on knowledge acquired in former situations and product generations. An adjustment in the manifestation of knowledge transfers in its concrete situation, here called intervention, therefore can directly be connected to the adequate speed optimization of knowledge-intensive process steps. This contribution presents the specification of seven concrete interventions following an intervention template. Further, it describes the design and results of a workshop with experts as a descriptive study. The workshop was used to assess the practical relevance of interventions designed as well as the identification of practical success factors and barriers of their implementation.},
  language  = {en}
}
@misc{BohlkenWeberRappetal.2015,
  author    = {Bohlken, Jens and Weber, Simon and Rapp, Michael A. and Kostev, Karel},
  title     = {Continuous treatment with antidementia drugs in Germany 2003-2013},
  series = {Postprints der Universit{\"a}t Potsdam : Humanwissenschaftliche Reihe},
  journal   = {Postprints der Universit{\"a}t Potsdam : Humanwissenschaftliche Reihe},
  number    = {522},
  issn      = {1866-8364},
  doi       = {10.25932/publishup-41471},
  url       = {http://nbn-resolving.de/urn:nbn:de:kobv:517-opus4-414718},
  pages     = {8},
  year      = {2015},
  abstract  = {Background: Continuous treatment is an important indicator of medication adherence in dementia. However, long-term studies in larger clinical settings are lacking, and little is known about moderating effects of patient and service characteristics. Methods: Data from 12,910 outpatients with dementia (mean age 79.2 years; SD = 7.6 years) treated between January 2003 and December 2013 in Germany were included. Continuous treatment was analysed using Kaplan-Meier curves and log-rank tests. In addition, multivariate Cox regression models were fitted with continuous treatment as dependent variable and the predictors antidementia agent, age, gender, medical comorbidities, physician specialty, and health insurance status. Results: After one year of follow-up, nearly 60\% of patients continued drug treatment. Donezepil (HR: 0.88; 95\% CI: 0.82-0.95) and memantine (HR: 0.85; 0.79-0.91) patients were less likely to be discontinued treatment as compared to rivastigmine users. Patients were less likely to be discontinued if they were treated by specialist physicians as compared to general practitioners (HR: 0.44; 0.41-0.48). Younger male patients and patients who had private health insurance had a lower discontinuation risk. Regarding comorbidity, patients were more likely to be continuously treated with the index substance if a diagnosis of heart failure or hypertension had been diagnosed at baseline. Conclusions: Our results imply that besides type of antidementia agent, involvement of a specialist in the complex process of prescribing antidementia drugs can provide meaningful benefits to patients, in terms of more disease-specific and continuous treatment.},
  language  = {en}
}
@article{BohlkenWeberRappetal.2015,
  author    = {Bohlken, Jens and Weber, Simon and Rapp, Michael A. and Kostev, Karel},
  title     = {Continuous treatment with antidementia drugs in Germany 2003-2013: a retrospective database analysis},
  series = {International psychogeriatrics},
  volume    = {27},
  journal   = {International psychogeriatrics},
  number    = {8},
  publisher = {Cambridge Univ. Press},
  address   = {New York},
  issn      = {1041-6102},
  doi       = {10.1017/S1041610215000654},
  pages     = {1335 -- 1342},
  year      = {2015},
  abstract  = {Background: Continuous treatment is an important indicator of medication adherence in dementia. However, long-term studies in larger clinical settings are lacking, and little is known about moderating effects of patient and service characteristics. Methods: Data from 12,910 outpatients with dementia (mean age 79.2 years; SD = 7.6 years) treated between January 2003 and December 2013 in Germany were included. Continuous treatment was analysed using Kaplan-Meier curves and log-rank tests. In addition, multivariate Cox regression models were fitted with continuous treatment as dependent variable and the predictors antidementia agent, age, gender, medical comorbidities, physician specialty, and health insurance status. Results: After one year of follow-up, nearly 60\% of patients continued drug treatment. Donezepil (HR: 0.88; 95\% CI: 0.82-0.95) and memantine (HR: 0.85; 0.79-0.91) patients were less likely to be discontinued treatment as compared to rivastigmine users. Patients were less likely to be discontinued if they were treated by specialist physicians as compared to general practitioners (HR: 0.44; 0.41-0.48). Younger male patients and patients who had private health insurance had a lower discontinuation risk. Regarding comorbidity, patients were more likely to be continuously treated with the index substance if a diagnosis of heart failure or hypertension had been diagnosed at baseline. Conclusions: Our results imply that besides type of antidementia agent, involvement of a specialist in the complex process of prescribing antidementia drugs can provide meaningful benefits to patients, in terms of more disease-specific and continuous treatment.},
  language  = {en}
}